NeuroMetrix To Exhibit at Medtrade Tradeshow and Conference

NeuroMetrix To Exhibit at Medtrade Tradeshow and ConferenceWALTHAM, Mass.--(BUSINESS WIRE)--Sep. 30, 2013-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the treatment and management of chronic pain, peripheral neuropathies, and related neurological disorders, today announced that it will exhibit at the annual fall Medtrade trade show and conference on October 8-10 in Orlando. Medtrade is the largest home medical equipment (HME) tradeshow and conference in the US. It brings together hundreds of HME manufacturers and thousands of durable medical equipment (DME) providers with home health care professionals for an annual product review and sourcing opportunity. The SENSUS™ Pain Management System will be presented in the “Product Spotlight” at the Medtrade New Product Pavilion.

SENSUS is a convenient and wearable non-invasive electrical nerve stimulator that offers patients a fast-acting, non-narcotic option for relief from chronic pain. The device is lightweight and can be worn during the day while remaining active, or at night while sleeping. It is specifically designed for people with diabetes that suffer from chronic pain. The most common cause of such pain is painful diabetic neuropathy (PDN), which affects up to 5 million people in the U.S. alone.

NeuroMetrix intends to use the conference as an opportunity to meet DME providers and distributors interested in adding SENSUS to their product offerings. The company’s representatives at Medtrade will include Shai N. Gozani M.D., Ph.D., NeuroMetrix President and Chief Executive Officer. The conference will be held at the Orange County Convention Center in Orlando, Florida and the NeuroMetrix exhibition will be at location #1263 on the tradeshow floor. Further information on Medtrade is available at: http://www.medtrade.com/show/about-the-show.shtml

About NeuroMetrix

NeuroMetrix is a medical device company that develops and markets home use and point-of-care devices for the treatment and management of chronic pain, peripheral neuropathies, and associated neurological disorders. The Company is presently focused on diabetic neuropathies, which affect over 50% of people with diabetes. If left untreated, diabetic neuropathies trigger foot ulcers that may require amputation and cause disabling chronic pain. The annual cost of diabetic neuropathies has been estimated at $14 billion in the United States. The company markets the SENSUS™ Pain Management System for treating chronic pain, focusing on physicians managing patients with painful diabetic neuropathy. The company also markets the DPNCheck^® device, which is a rapid, accurate, and quantitative point-of-care test for diabetic neuropathy. This product is used to detect diabetic neuropathy at an early stage and to guide treatment. For more information, please visit http://www.neurometrix.com.

Source: NeuroMetrix

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com